Form 4: Director Kieran Gallahue Increases Stake in Edwards Lifesciences

Director Kieran Gallahue acquired 4,315 shares of Edwards Lifesciences common stock through restricted stock unit and award grants.

Summary

• Director Kieran Gallahue received a grant of 3,251 restricted stock units (RSUs) on May 8, 2026.
• Director Kieran Gallahue received a grant of 1,064 restricted stock awards on May 8, 2026.
• Both grants were issued under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program.
• The securities are scheduled to vest fully after one year or at the next annual meeting of stockholders, whichever occurs first.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral, routine disclosure of director equity compensation that does not signal a change in company strategy or financial health.

Positives

• Alignment of director interests with shareholders through equity-based compensation.
• Demonstrates long-term commitment from a member of the Board of Directors.

Negatives

• None identified; this is a standard equity compensation disclosure for a director.

Risks

• Vesting is subject to the director's continued service with the company.

Future Outlook

The securities are expected to vest in one year or upon the next annual meeting of stockholders.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are a standard corporate governance practice in the medical device industry to ensure board members maintain a vested interest in company performance.

Comparison to Industry Standards

• The grant structure aligns with standard compensation practices for S&P 500 companies.
• The use of a one-year vesting schedule is consistent with typical director retention policies in the healthcare sector.

Stakeholder Impact

• Positive signal to shareholders regarding director alignment with long-term company performance.

Next Steps

• Vesting of the granted shares in one year or at the next annual meeting of stockholders.

Key Dates

Keywords

Edwards Lifesciences, EW, Form 4, Insider Trading, Director Compensation, Equity Grant